Malignant lung cancer carries a poor prognosis with a 5-year survival rate of about 18%. This new method proposes an innovative minimally invasive procedure for the transcutaneous ablation of lung tumor masses with complete removal or significant debulking of the masses. This new procedure could increase lung cancer survival rates and at the same time decrease morbidity and side effects associated with current treatment therapies. It will also provide a viable treatment for a large group of patients that cannot tolerate resection surgery, radiotherapy and chemotherapy, or who have had prior radiation and cannot have additional radiation to that region.
This abstract and the presentation materials are available to members only; a login is required.